MPLT
NASDAQMapLight Therapeutics Inc.
News · 26 weeks90+225%
2026-04-192026-10-11
Mix4190d
- Insider19(46%)
- SEC Filings12(29%)
- Other5(12%)
- Analyst4(10%)
- Offering1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by MapLight Therapeutics Inc.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by MapLight Therapeutics Inc.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by MapLight Therapeutics Inc.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by MapLight Therapeutics Inc.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by MapLight Therapeutics Inc.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 4 filed by MapLight Therapeutics Inc.4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- ANALYSTGuggenheim initiated coverage on MapLight TherapeuticsGuggenheim initiated coverage of MapLight Therapeutics with a rating of Neutral
- PRMapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of OptogeneticsAward honors foundational discoveries in optogenetics and circuit mapping These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (NASDAQ:MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning light-gated ion channels and optogeneti
- SECSEC Form EFFECT filed by MapLight Therapeutics Inc.EFFECT - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECSEC Form 424B3 filed by MapLight Therapeutics Inc.424B3 - MapLight Therapeutics, Inc. (0001770069) (Filer)
- INSIDERGeneral Counsel Hanson Kristopher sold $192,660 worth of Voting Common Stock (16,509 units at $11.67) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 137,044 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECAmendment: SEC Form S-1/A filed by MapLight Therapeutics Inc.S-1/A - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECSEC Form S-1 filed by MapLight Therapeutics Inc.S-1 - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Therapeutics to Participate in Upcoming Investor ConferenceSAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conference: Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)Date: Monday, September 14th Format: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & Presentations" page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations. About MapLight Therapeutics MapLight Therapeutics is a clinical-stage bio
- INSIDERChief Discovery Officer Kreitzer Anatol was granted 6,020 units of Voting Common Stock, increasing direct ownership by 3% to 180,926 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERCAO and Interim CFO Gillis Jonathan was granted 8,242 units of Voting Common Stock, increasing direct ownership by 6% to 152,482 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Executive Officer Kroeger Christopher A. was granted 23,145 units of Voting Common Stock, increasing direct ownership by 2% to 1,269,600 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERGeneral Counsel Hanson Kristopher was granted 7,730 units of Voting Common Stock, increasing direct ownership by 5% to 153,553 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Medical Officer Foff Erin Pennock was granted 13,360 units of Voting Common Stock, increasing direct ownership by 4% to 312,261 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Scientific Officer Lillie James Woodruff was granted 7,730 units of Voting Common Stock, increasing direct ownership by 4% to 210,110 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERLarge owner Catalyst4, Inc. bought $50,072,000 worth of Voting Common Stock (4,400,000 units at $11.38) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 10-Q filed by MapLight Therapeutics Inc.10-Q - MapLight Therapeutics, Inc. (0001770069) (Filer)
MPLT FAQ
6 questionsWhere does MPLT stock trade?
MapLight Therapeutics Inc. (MPLT) is listed on NASDAQ.What sector and industry is MPLT in?
MapLight Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MapLight Therapeutics Inc. go public?
MapLight Therapeutics Inc. (MPLT) completed its IPO in 2025.What are analysts saying about MPLT?
MapLight Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Neutral on 2026-10-06. Recent price targets range from $1300.00 to $4800.00.What companies are similar to MPLT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MPLT side-by-side with any of them on Quantisnow.How can I track MPLT on Quantisnow?
Quantisnow aggregates MapLight Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MPLT to receive live email and push alerts on every new disclosure.